Parnerships & Collaboration
AVEROA entered into two major agreements
with AKEBIA Therapeutics, Inc. [AKBA], a US-based company that granted AVEROA to develop and commercialize AVA1014 in Europe, UK, Switzerland and Turkey.
Research collaboration and license agreement with IDIBELL for the development of a biomarker and a new treatment for renal lithiasis.
By identifying and in-licensing late-stage drugs that have a strong therapeutic and commercial fit with our current portfolio.
By positioning products in unprecedent indications by relying on products mechanisms of action and the knowledge of renal pathologies using sophisticated tools to achieve a global therapeutic action
By a smart and adapted registration strategy to optimize the targeted indications, the road to approval and the global value of the products
By generating industrial property and ensuring market protection
By developing a network of commercial partners and distributors to maximize the potential of our registered products.
Co-founder of Advicenne in 2007 and Panntherapi in 2020, he is an expert in the clinical development of innovative products for pharmaceutical and biotech industry. He has conducted many clinical studies and has successfully conducted numerous drug development programs in the field of the central nervous system (CNS) and kidney diseases. In particular, he successfully conducted the proof-of-concept study of the « Blockbuster » duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. His long history of interactions with the U.S. FDA and European (EMA) regulatory agencies provides Averoa with a strategic regulatory vision that is essential to its development.
